Company profile: Shape Therapeutics
1.1 - Company Overview
Company description
- Provider of AI-enabled RNA therapeutics and gene therapy technologies, including the ShapeTX AI Engine for data-driven medicine development; RNA Medicines for discovery and design; RNAfix recruiting ADAR to recode RNA; RNAskip suppressor tRNA addressing premature stop codons; RNAswap smart-sensing vectors for tailored gene expression; and Precise Delivery engineered capsids for targeted RNA delivery.
Products and services
- RNA Medicines: AI-guided therapeutics program that utilizes RNA technology to discover and design new medicines that are effective and safe
- Precise Delivery: Custom-engineered, AI-driven platform that engineers viral capsids to deliver RNA medicines precisely to specific tissues or cells for accurate targeting
- ShapeTX AI Engine: Enterprise-grade AI engine that analyzes datasets across technology suites and therapeutic portfolios to inform decision-making in medicine development
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Shape Therapeutics
Remedy Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage small molecule drug therapies for acute central nervous system disorders, developing treatments that target NCCa-ATP channels in traumatic brain injury, stroke, and spinal cord injury, including RP-1127, an intravenous glyburide inhibitor acting through type-1 sulfonylurea antagonism.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Remedy Pharmaceuticals company profile →
Synaptive Medical
HQ: Canada
Website
- Description: Provider of neurosurgery, medical imaging and surgical navigation solutions, including the Synaptive Integrated Suite to integrate information and automation across interventions; Modus X robotic exoscope with 4K 3D and fluorescence visualization; Modus Plan automatic tractography segmentation; Modus Nav instrument tracking via intraoperative tractography; Synaptive MRI point-of-care MRI; ImageDrive zero-footprint HTML5 viewer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synaptive Medical company profile →
Vivoryon Therapeutics
HQ: Germany
Website
- Description: Provider of biopharmaceutical R&D and clinical development focused on small molecule medicines for Alzheimer’s disease and cancer, including varoglutamstat (QPCT inhibitor, Phase 2) and a portfolio of QPCT/L inhibitors, supported by a comprehensive clinical program. Holds a strategic licensing partnership with Simcere for varoglutamstat and a preclinical monoclonal N3pE‑antibody in Greater China.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vivoryon Therapeutics company profile →
Satsuma Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical development for migraine, advancing STS101, a drug-device combination featuring a proprietary dry-powder formulation of dihydroergotamine (DHE) for the acute treatment of migraine, self-administered via a pre-filled, single-use nasal delivery device.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Satsuma Pharmaceuticals company profile →
Semnur Pharma
HQ: United States
Website
- Description: Provider of specialty pharmaceutical development focused on the clinical and commercial advancement of innovative products for pain management, including SP-102 (SEMDEXA), a non-opioid injectable corticosteroid gel designed to treat moderate to severe chronic radicular pain/sciatica via epidural injection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Semnur Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Shape Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Shape Therapeutics
2.2 - Growth funds investing in similar companies to Shape Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Shape Therapeutics
4.2 - Public trading comparable groups for Shape Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →